Novel drug discovery screening method, novel drug discovery screening system, and novel drug discovery screening control device

The method estimates cell states by correlating morphological and molecular information, bypassing genetic analysis, enhancing drug discovery efficiency and accuracy by identifying unique cell populations.

JP7581619B2Active Publication Date: 2024-11-13YOKOGAWA ELECTRIC CORP
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
JP2019230347
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-12-20
Publication Date
2024-11-13
Estimated Expiration
2039-12-20

AI Technical Summary

Technical Problem

Existing drug discovery screening methods require genetic analysis to evaluate cell states, which is time-consuming and may not accurately reflect the true state of individual cells.

Method used

A method that estimates cell states by associating morphological information, such as cell shape and position, with molecular information like genetic data, without the need for genetic analysis, using a drug discovery screening system that photographs, suctions, and analyzes cells to create a database correlating these features.

Benefits of technology

Enables rapid estimation of cell states without genetic analysis, improving efficiency and accuracy in drug discovery by identifying unique cell populations and reducing the need for extensive testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007581619000001
    Figure 0007581619000001
  • Figure 0007581619000002
    Figure 0007581619000002
  • Figure 0007581619000003
    Figure 0007581619000003
Patent Text Reader

Abstract

To provide a novel drug discovery screening method that can estimate the state of a cell without performing genetic analysis.SOLUTION: The novel drug discovery screening method includes: photographing a cell sample with a candidate drug added to a cell sample; sucking cells; performing image processing on the captured image; obtaining morphological information on the shape of the cells contained in the cell sample based on the image processing result; selecting one cell to be sucked based on the morphological information; sucking the selected one cell; analyzing the sucked one cell; extracting characteristic values of acquired molecular information and morphological information based on the analyzed results; creating a database of cell shape for each cell by storing in the database the morphological information, the molecular information and the feature values in association with one another; and estimating the state of the cells in the sample by referring to the database using the morphological information obtained based on the results of image processing on the image taken of the sample.SELECTED DRAWING: Figure 12
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel drug discovery screening method. , novel drug discovery screening system, and novel drug discovery screening control device - Patents.com Regarding. [Background technology]

[0002] In evaluation tests for cell stimulation using live cells, the quantification of labeled known genes and proteins and prediction of cell states are performed using changes in morphology as indicators. In evaluation tests for cell stimulation using live cells, for example, a cell population whose morphology has changed due to stimulation is collected and the genes, which are one of the intracellular substances, are analyzed to confirm the detailed state of the cells.

[0003] The following devices have been proposed to confirm the detailed state of cells. For example, a drug discovery screening device has been proposed in which a plate containing samples (cells) is removed from an image measurement unit and an incubator unit integrally connected to the image measurement unit, sent to the image measurement unit, measured by the image measurement unit, and then returned to the incubator unit (see, for example, Patent Document 1).

[0004] In addition, a cell concentration and purification device has been proposed that has the function of image-based recognition of the shape and fluorescent emission of individual cells, and the function of recognizing the target cells based on the shape and fluorescent emission information to separate and purify them (see, for example, Patent Document 2).

[0005] In addition, a cell detection device has been proposed which captures an image derived from a cell obtained by irradiating the cell with a cell irradiation means, performs a two-dimensional Fourier transform on the captured image, and detects a target cell based on the spatial frequency distribution of the image converted by an image conversion means (see, for example, Patent Document 3). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2010-210237 A [Patent Document 2] JP 2015-051008 A [Patent Document 3] JP 2017-108738 A Summary of the Invention [Problem to be solved by the invention]

[0007] However, in the techniques described in Patent Documents 1 to 3, for example, a floating cell population that has changed in morphology due to a stimulus is collected, and the collected cell population is subjected to analysis such as genetic analysis. In addition, in the techniques described in Patent Documents 1 to 3, an operator is required to evaluate the state of the cells, for example, by looking at an image of the cells and whether the cells are differentiated or undifferentiated.

[0008] The present invention has been made in consideration of the above problems, and provides a novel drug discovery screening method capable of estimating the state of a cell without carrying out genetic analysis or the like. , novel drug discovery screening system, and novel drug discovery screening control device - Patents.com The purpose is to provide. [Means for solving the problem]

[0009] In order to achieve the above-mentioned object, a novel drug discovery screening method according to one embodiment of the present invention comprises: photographing a cell sample to which a candidate drug has been added, aspirating cells contained in the cell sample, performing image processing on the photographed image, acquiring morphological information relating to the shape of the cells contained in the cell sample based on the results of the image processing, selecting one cell to be aspirated based on the morphological information, aspirating the selected one cell, analyzing the aspirated one cell, extracting features of the molecular information and the morphological information acquired based on the results of the analysis, correlating the morphological information, the molecular information, and the features for each cell and storing them in a database to create a database relating to the shapes of the cells; photographing a screening sample, which is a sample to which a candidate drug has been added, to include a plurality of the cell samples; and using the morphological information acquired based on the results of image processing on the photographed image, by referring to the database, estimating the state of the cells contained in the sample.

[0010] Furthermore, in a novel drug discovery screening method according to one embodiment of the present invention, the morphological information includes information indicating the position of a cell or the position of a nucleus, and may be at least one of a cell area, a nuclear area, a cell circumference, a nuclear circumference, a cell's major axis, a nuclear major axis, a cell's minor axis, a nuclear minor axis, a cell's apex ratio, a nuclear apex ratio, etc.

[0011] In addition, in a novel drug discovery screening method according to one embodiment of the present invention, the molecular information may be at least one of gene information, protein information, peptide information, amino acid information, lipid information, carbohydrate information, mass information, etc.

[0012] In addition, in the novel drug discovery screening method according to one aspect of the present invention, the molecular information may be genetic information, and the feature amount may be a correlation coefficient between the shape information and the genetic information. Effect of the Invention

[0013] According to the present invention, it is possible to provide a novel drug discovery screening method capable of estimating the state of a cell without carrying out genetic analysis or the like. [Brief description of the drawings]

[0014] [Figure 1] 1 is a block diagram showing an example of the configuration of a drug discovery screening system according to a first embodiment. [Diagram 2] 4 is a diagram showing an example of the configuration of an imaging and suction unit according to the first embodiment; FIG. [Diagram 3] FIG. 13 is a diagram showing an example of an image of an entire sample according to the embodiment; [Figure 4] 1A and 1B are diagrams illustrating examples of images captured by magnification photography according to an embodiment. [Diagram 5] FIG. 13 is a diagram showing an example of a process for aspirating cells. [Figure 6] 4 is a diagram showing an example of information stored in a DB according to the first embodiment; FIG. [Figure 7] FIG. 11 is a diagram showing an example of a correlation coefficient calculated from information stored in a DB according to the first embodiment. [Figure 8] FIG. 2 is a diagram showing an example of characteristics of a cell having a gene stored in a DB according to the first embodiment. [Figure 9] FIG. 2 is a diagram showing an example of cell characteristic information for morphological information stored in a DB according to the first embodiment. [Figure 10] 11 is a flowchart of a DB creation process according to the first embodiment. [Figure 11] 1 is a flowchart of an evaluation procedure for evaluating a sample using a DB according to the first embodiment. [Figure 12] 13 is a schematic flowchart of a drug discovery screening process according to a second embodiment. [Figure 13] 13 is a flowchart of a drug discovery screening process according to the second embodiment. [Figure 14] 13 is a flowchart of a drug discovery screening process according to the second embodiment. [Figure 15] 13 is a flowchart of a selection process of cells to be aspirated according to the second embodiment. [Figure 16] FIG. 11 is a diagram showing an example of morphological information according to the second embodiment. [Figure 17] 10 is a flowchart of a process according to a modified example of the second embodiment. [Figure 18] 13 is a flowchart of a drug discovery screening process according to the third embodiment. [Figure 19] 13 is a flowchart of a drug discovery screening process according to the third embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Hereinafter, an embodiment of the present invention will be described with reference to the drawings. In the drawings used in the following description, the scale of each component is appropriately changed so that each component is of a recognizable size.

[0016] First Embodiment First, an outline of this embodiment will be described. In this embodiment, an example of a drug discovery screening system creating a database will be described. In this embodiment, a captured image of a sample is subjected to image analysis to obtain morphological information, and one cell is aspirated and genetically analyzed to obtain genetic information. In this embodiment, the morphological information and genetic information are associated with each other and stored in a database (DB), and features of the information stored in the DB (e.g., correlation coefficients) are extracted. In this embodiment, the extracted features are associated with the information stored in the DB and stored. In this embodiment, the state of the cells (e.g., differentiated, undifferentiated) is estimated by referring to the DB thus created using morphological information extracted from the image of the sample. That is, in this embodiment, the state of the cells can be estimated without analyzing the cells contained in the sample with an analysis device.

[0017] [Example of the configuration of drug discovery screening system 1] Fig. 1 is a block diagram showing an example of the configuration of a drug discovery screening system 1 according to this embodiment. As shown in Fig. 1, the drug discovery screening system 1 includes a control device 2, an imaging and aspirating device 3 (imaging section, aspirating section), an analysis device 4-1, an analysis device 4-2, ..., and a DB 5. In the following description, when one of the analysis devices 4-1, 4-2, ... is not specified, it will be referred to as an analysis device 4. Note that the drug discovery screening system 1 includes at least one analysis device 4.

[0018] The control device 2 includes an operation unit 21 , a display unit 22 , a suctioned cell selection unit 23 , a DB creation unit 24 , a feature extraction unit 25 , an estimation unit 26 , and a control unit 27 . The imaging and suction device 3 includes a control unit 31 , an imaging and suction unit 32 , and an image analysis unit 33 . The control device 2 and the imaging and suction device 3 are connected to each other via a wired or wireless line. The control device 2 and the analysis device 4 are connected to each other via a wired or wireless line.

[0019] [Operation and functions of each component of Drug Discovery Screening System 1] Next, the operation and function of each component device of the drug discovery screening system 1 will be described.

[0020] First, the operation and functions of the control device 2 will be described. The control device 2 controls the imaging and suction device 3 and the analysis device 4 .

[0021] The control unit 27 outputs an instruction to the imaging and suction device 3 to capture an image of the sample, and obtains the captured image and the image processing result for the captured image from the imaging and suction device 3. The image processing result includes position information indicating the position of the cell or tissue in the cell culture well plate 5 (FIG. 2) and morphological information regarding the shape of the cell or tissue. The morphological information includes information indicating the position of the cell or the position of the nucleus. The morphological information includes at least one of information such as cell area, nucleus area, cell perimeter, nucleus perimeter, cell major axis, nucleus major axis, cell minor axis, nucleus minor axis, cell apex ratio, nucleus apex ratio, etc. The control unit 27 causes the display unit 22 to display the captured image and the image processing result, for example. The control unit 27 may obtain information indicating whether the cell used in the analysis is differentiated or undifferentiated based on the operation result of the user operating the operation unit 21 based on the displayed image.

[0022] The aspirated cell selection unit 23 determines whether or not there are cells or tissues to be aspirated based on the acquired image processing results, and when it determines that there are cells or tissues to be aspirated, outputs an aspirating instruction to aspirate the cells or tissues to be aspirated to the imaging and aspirating device 3. Note that the objects to be aspirated are not limited to cells or tissues, and may include surrounding compounds, culture fluid, etc. The aspirated cell selection unit 23 outputs an analysis instruction to the analysis device 4 to analyze the aspirated cells. The control device 2 acquires the analysis result from the analysis device 4. The analysis result includes molecular information contained in the analyzed cells or tissues. The molecular information is at least one of genetic information, protein (including antibodies, cytokines, enzymes, etc.) information, peptide information, amino acid information, lipid information, carbohydrate information, mass information, etc. The aspirated cell selection unit 23 may select the cells to be aspirated based on the result of the user operating the operation unit 21 while looking at the captured image displayed on the display unit 22.

[0023] The DB creation unit 24 associates the morphological information with the genetic information and stores them in the DB 5.

[0024] The feature extraction unit 25 obtains features by calculating correlation coefficients between each item of morphological information (e.g., cell area, cell length) and genetic information (gene A, gene B). The feature extraction unit 25 stores the obtained correlation coefficients in DB5 in association with the information stored in DB5. The feature extraction unit 25 acquires information indicating whether the cells used in the analysis are differentiated or undifferentiated, based on the correlation coefficient and the information stored in the DB5. The feature extraction unit 25 stores information indicating whether the tissue is differentiated or undifferentiated in the DB 5 in association with the morphological information stored in the DB 5.

[0025] The operation unit 21 is, for example, at least one of a touch panel sensor, a keyboard, a mouse, etc., provided on the display unit 22. The operation unit 21 acquires the result of an operation performed by a user.

[0026] The display unit 22 is, for example, a liquid crystal image display device, an organic EL (Electro Luminescence) image display device, or the like.

[0027] The estimation unit 26 estimates the state of the cells (e.g., differentiated, undifferentiated) by referring to the morphological information of the image of the sample with the reagent attached, which is stored in the DB 5. The estimation unit 26 displays the estimated result on the display unit 22.

[0028] DB5 is a database. DB5 stores morphological information and genetic information for each analyzed cell in association with each other. DB5 stores morphological information and genetic information in association with a correlation coefficient between the morphological information and the genetic information. DB5 stores information indicating whether a cell is differentiated or undifferentiated in association with the morphological information. As described below, DB5 stores each gene name in association with the characteristics of the cells that contain that gene.

[0029] Next, the operation and function of the photographing and suction device 3 will be described. The control unit 31 controls the imaging and aspirating unit 32 to photograph the set sample in response to an imaging instruction output by the control device 2. The image analysis unit 33 performs image processing on the photographed image to obtain morphological information. The control unit 31 outputs the image processing result including the image photographed by the imaging and aspirating unit 32 and the morphological information obtained by the image analysis unit 33 to the control device 2. The detailed configuration of the imaging and aspirating unit 32 will be described later with reference to FIG. 2.

[0030] The image analysis unit 33 performs image processing on the captured image to obtain morphological information. The image processing performed by the image analysis unit 33 includes, for example, binarization, edge detection, feature amount detection, clustering, and the like.

[0031] Next, the operation and functions of the analysis device 4 will be outlined. The analysis device 4 performs analysis on the cells or tissues aspirated by the imaging and aspirating device 3. The analysis device 4 is, for example, a DNA (DeoxyriboNucleic Acid) analysis device, an RNA (RiboNucleic Acid) analysis device, a protein analysis device, or the like. The analysis device 4 outputs the analysis results to the control device 2. The analysis device 4 is equipped with, for example, a transport unit that transports the sample, a control unit that controls the transport unit, and the like.

[0032] [Other examples of features] The calculation of the feature amount is not limited to the calculation of the correlation coefficient described above, and may use a statistical method such as clustering analysis, principal component analysis, and multivariate analysis, or may use machine learning (Deep Learning, etc.). The feature amount extraction unit 25 may separate data by cell type or type of added reagent before calculating the feature amount. Specifically, the table shown in FIG. 6, which will be described later, may be used separately for each type of cell tumor or reagent. By dividing the data into layers in this way, it is possible to obtain an effect of clarifying the characteristics of the data. The feature amount extraction unit 25 may perform clustering analysis on the information stored in the DB5 to group the data, and then obtain a correlation coefficient within each group. Specifically, the table shown in FIG. 6, which will be described later, is created from morphological information and genetic information, clustering is performed, and the correlation coefficient within the group is calculated, thereby obtaining an effect of clarifying where the differences exist between the groups.

[0033] [Analysis target, analysis method] Here, an example of a subject of analysis and an example of an analysis method performed by the analysis device 4 will be described. First, an example of a subject of analysis will be described. The analysis device 4 performs analysis, for example, of compounds possessed or produced by the acquired cells. The analysis device 4 performs analysis, for example, of compounds produced by the acquired surrounding cells. The analysis device 4 performs analysis, for example, of compounds added to the culture supernatant of the acquired cells. The analysis device 4 performs analysis, for example, of compounds administered to the individual of the acquired cells or ingested by the individual.

[0034] The analysis targets are organic or inorganic compounds contained in the compound. The analysis targets are proteins (including antibodies, cytokines, enzymes, etc.), peptides, amino acids, lipids, carbohydrates, DNA, RNA (including mRNA, ncRNA, rRNA, tRNA, etc.) contained in the organic compound, candidate compounds to be screened, etc. ncRNA includes lncRNA, siRNA, miRNA, piRNA, etc. The analysis targets are salts, metal ions, etc. contained in the inorganic compound.

[0035] The analysis device 4 may perform at least one of the following analyses: mass spectrometry, NMR (Nuclear Magnetic Resonance), liquid chromatography, Raman spectroscopy, infrared spectroscopy, electrophoresis, and elemental analysis. The mass spectrometry is, for example, an ionization method. The ionization method includes EI (electron ionization), CI (chemical ionization), FAB (fast atom bombardment), ESI (electrospray ionization), and MALDI (matrix-assisted laser desorption ionization). In addition, in mass spectrometry, two mass spectrometers (MS) may be connected in series, and an apparatus having a collision activation chamber between them may be used for analysis.

[0036] The analysis device 4 uses techniques such as NGS (next generation sequencer), qPCR (quantitative polymerase chain reaction), microarray, digital PCR, sequencer, etc., in the analysis of DNA and RNA. In addition, a reverse transcription process may be included in the analysis of RNA. In addition, the introduction method for mass spectrometry may be direct introduction or a method connected to liquid chromatography.

[0037] [Example of configuration of the imaging and suction unit 32] Next, a configuration example of the imaging and suction unit 32 will be described. 2 is a diagram showing an example of the configuration of the imaging and aspirating unit 32 according to this embodiment. As shown in FIG. 2, the imaging and aspirating unit 32 includes an image cell acquisition unit 321, an aspirating unit 322, an XYZ stage 323, an aspirating tip 324, a tip rack 325, a sample rack 326, and a cell culture well plate 5. The cell image acquisition unit 321 includes an imaging unit 3211, a bright field illumination 3212, and an XY stage 3213. In Fig. 2, the plane along which the XYZ stage 323 moves is the xy plane, and the direction perpendicular to the xy plane is the z-axis direction. The left-right direction of the page is the x-axis direction, and the depth direction is the y-axis direction.

[0038] [Operation and function of each component of the imaging and suction unit 32] A specimen in which a candidate drug is added to a sample of a plurality of cells 51 is placed on the cell culture well plate 5. The specimen may contain a cell culture solution 52.

[0039] The imaging and suction unit 32 captures an image of the entirety or an image of a specific region in the cell culture well plate 5 placed on the XY stage 3213 in response to an imaging instruction from the control unit 31, and outputs the captured image to the image analysis unit 33. Any cell culture vessel may be placed on the XY stage 3213, and is not limited to the cell culture well plate 5, and may be a cell culture dish, a cover glass chamber, a petri dish, or the like. The imaging and suction unit 32 drives the XY stage 3213 and the suction unit 322 to suction the cells or tissue to be suctioned in response to the control of the control unit 31. The imaging and suction unit 32 drives the XY stage 3213 and stores the suction tip 324 containing the suctioned cells or tissue in the sample rack 326 in response to the control of the control unit 31.

[0040] The photographing unit 3211 includes, for example, a microscopic optical unit, a confocal scanning unit, a photographing unit, a fluorescent light source, and an objective lens, as described in JP 2019-41691 A. The control device 2 includes, for example, a suction time setting unit and a suction pressure setting unit, as described in JP 2019-41691 A. With these configurations, the photographing and suction unit 32 can suction cells or tissues from a sample with less stress, as with the cell suction support device described in JP 2019-41691 A.

[0041] [Determining which cells to aspirate] Next, a description will be given of an example of a method for determining cells or tissues aspirated by the drug discovery screening system 1. In the following description, an example in which the objects of aspirating and analyzing are cells will be described.

[0042] First, for example, an operator sets the cell culture well plate 5 on the XY stage 3213. Then, the imaging and suction unit 32 outputs information indicating that the cell culture well plate 5 has been set on the XY stage 3213 to the control device 2. When the cell culture well plate 5 is set on the photographing and suctioning section 32, the control device 2 outputs to the photographing and suctioning section 32 an instruction to photograph the entire sample.

[0043] As shown in Fig. 3, the photographing unit 3211 photographs the entire sample according to the control of the control unit 31 that has acquired a photographing control instruction. Fig. 3 is a diagram showing an example of an image of the entire sample according to the embodiment. In Fig. 3, the region g101 is, for example, a region of cells in a state where the effect of a drug is manifested (cells in a first state). The regions g111 and g112 are, for example, a region of cells in a state where the effect of a drug is not manifested (cells in a second state). In Fig. 3, the longitudinal direction is the x direction and the transverse direction is the y direction.

[0044] The image analysis unit 33 performs image processing on the captured image to obtain information regarding, for example, the size of the cell. The control device 2 selects, for example, a cell whose cell area is larger than a predetermined value as the suction target. The control device 2 outputs an instruction to the photographing and aspirating device 3 to take an enlarged photograph of an area (suction candidate) including the selected cell. The control unit 31 of the photographing and aspirating device 3 obtains the instruction to take an enlarged photograph of the area including the selected cell.

[0045] As shown in Fig. 4, the photographing unit 3211 photographs the entire sample at a magnification higher than that at which the entire sample is photographed in response to an instruction from the control unit 31. The photographing unit 3211 sets the magnification at which the entire sample is photographed to, for example, 10 times, and sets the magnification at which the suction candidate is photographed to, for example, 100 times. Note that, if the resolution of the image sensor of the photographing unit 3211 is high, the photographing unit 3211 does not need to photograph the enlarged photograph. In this case, the image analysis unit 33 may extract and use an image of the region of the suction candidate from the entire image.

[0046] FIG. 4 is a diagram showing an example of an image of the enlarged photographing according to the embodiment. In FIG. 4, the region g101 and the region g111 are the same as those in FIG. 3. Furthermore, the reference symbol g121 indicates an image of the cytoplasm (cell membrane substrate), the reference symbol g122 indicates an image of the nucleus, and the reference symbol g123 indicates the center of the nucleus. Furthermore, in FIG. 4, the longitudinal direction is the x direction, and the transverse direction is the y direction. Note that the photographing unit 3211 may also photograph the region g112 in FIG. 3 according to the control of the control unit 31. Note that, when there are multiple suction candidates, the control unit 31 moves the XY stage 3213 in the xy plane to photograph the specific region.

[0047] The image analysis unit 33 performs image processing on the captured image of the suction candidate. Through this image processing, the image analysis unit 33 obtains the morphological information of the cell position (center coordinates (x1, y1) of the nucleus), the length of the long side and the short side in the xy plane, and the area of ​​the cell. In addition, as described in the above-mentioned JP 2019-41691 A, the image analysis unit 33 obtains the height of the nucleus by moving the objective lens of the imaging unit 3211 in the z direction and capturing the image. The image analysis unit 33 may perform the same processing on the region of the symbol g112 in FIG. 3. The control unit 31 outputs the morphological information acquired by the image analysis unit 33 to the control device 2.

[0048] The aspirating cell selection unit 23 of the control device 2 selects cells to be aspirated based on the morphological information. When there are two aspirating candidates as shown in FIG. 3, the aspirating cell selection unit 23 may select cells to be aspirated from one of the regions, or may select cells to be aspirated from both regions. In this way, the aspirating cell selection unit 23 selects cells to be aspirated. When there are multiple aspirating candidates, the aspirating cell selection unit 23 may select cells to be aspirated from the multiple aspirating candidates based on, for example, the shape of the nucleus, the size (area) of the nucleus, the position of the nucleus, the cell cycle state of the cell, and the like. The aspirating cell selection unit 23 outputs information of the cells selected as aspirating candidates (center coordinates of the nucleus, the lengths of the long and short sides in the xy plane, and the height in the z direction) to the imaging and aspirating device 3.

[0049] [Suction process] Next, the suction process performed by the imaging and suction unit 32 will be described. The imaging and suction section 32 mounts one of the plurality of suction tips 324 stored in the tip rack 325 to the suction section 322 in accordance with the control of the control section 31 . Next, the imaging and suction unit 32 moves the suction unit 322 and the XY stage 3213 under the control of the control unit 31 to suction the desired cell or tissue.

[0050] Fig. 5 is a diagram showing an example of a process for aspirating cells. In the example shown in Fig. 5, the position of the tip end 324a from the bottom surface in the z-axis direction is z3. In this case, the gap between the tip end 324a and the cell 51 is small, and the tip end 324a has not yet pierced the cell 51. The state shown in Fig. 5 is one in which the cell is adhered to the bottom surface 5a of the cell culture well plate 5. Reference numeral 324b denotes the wall of the suction tip 24.

[0051] The control unit 31 can reduce damage to the target when suctioning one cell by accurately controlling the z-axis direction of the tip end 324a at the start of suction as shown in Fig. 5. The control unit 31 obtains the optimal height by changing the height in the z-axis direction of the objective lens of the imaging unit 3211 and photographing, and controls the tip end 324a in this way in the z-axis direction at the start of suction.

[0052] Next, the imaging and aspirating section 32 stores the aspirating tip 324 that has aspirated the cells or tissue in a predetermined position in the sample rack 326 under the control of the control section 31 . Next, the control unit 31 outputs to the control device 2 information indicating that the cell or tissue has been aspirated.

[0053] [Analysis operation of analysis device 4] Next, the operation of the analysis device 4 will be described. The analysis device 4 acquires information indicating that the cells or tissues have been aspirated from the control device 2. The analysis device 4 performs, for example, genetic analysis by a known method on the cells or tissues aspirated by the imaging and aspirating unit 32. The analysis device 4 outputs the analyzed genetic information to the control device 2.

[0054] [Example of information stored in DB5] Next, an example of information stored in DB5 will be described. 6 is a diagram showing an example of information stored in the DB5 according to this embodiment. As shown in FIG. 6, the DB5 stores, for each cell, morphological information (cell area [μm 2 ] and the perimeter of the cell [μm]) and genetic information (gene A [pieces], gene B [pieces]) are stored in association with each other. Note that the morphological information shown in FIG. 6 is an example, and may be the length of the long side of the cell, the length of the short side of the cell, the area of ​​the nucleus, the perimeter of the nucleus, the length of the long side of the nucleus, the length of the short side of the nucleus, the apex ratio in the shape of the cell, the mass of the cell, etc. Furthermore, the genetic information may be information on genes or proteins contained in the aspirated cells, etc.

[0055] Next, a correlation coefficient will be described as an example of a feature quantity extracted from information stored in DB5 in FIG. Fig. 7 is a diagram showing an example of correlation coefficients calculated from information stored in DB5 according to this embodiment. As shown in Fig. 7, the feature extraction unit 25 of the control device 2 extracts each of the morphological information and genetic information stored in DB5, and calculates a correlation coefficient for each extracted item. The value used to calculate the correlation coefficient is, for example, the average value of each item.

[0056] For example, the feature extraction unit 25 determines that there is almost no correlation when the correlation coefficient is 0 to 0.2, determines that there is a weak correlation when the correlation coefficient is 0.2 to 0.4, determines that there is a slight correlation when the correlation coefficient is 0.4 to 0.7, and determines that there is a strong correlation when the correlation coefficient is 0.7 to 1.0. In the example shown in Figure 7, a strong negative correlation was confirmed between the circumference and gene B.

[0057] DB5 stores the name of each gene in association with the characteristics of cells having the gene, as shown in Fig. 8. Fig. 8 is a diagram showing an example of characteristics of cells having genes stored in DB5 according to this embodiment. For example, when gene B is a gene whose expression is confirmed only in undifferentiated cells, DB5 stores the name of gene B in association with "undifferentiation" as a characteristic. Note that, although the example shown in Fig. 8 shows examples of differentiation and "undifferentiation" as characteristics, the information indicating the characteristics is not limited to this.

[0058] Other information indicating characteristics is, for example, the adhesion area. In adherent cells, when the expression of genes expressed in epithelium, such as E-cadherin and Occludin, decreases, the adhesion ability of the cells decreases and the adhesion area of ​​the cells is thought to become smaller (their morphology is thought to become rounder). The decrease in gene expression of E-cadherin and Occludin is considered to be an indicator of EMT (epithelial-mesenchymal transition), and is generally thought to be related to development, wound healing, and carcinogenesis.

[0059] When a correlation as shown in FIG. 7 is obtained, the feature extraction unit 25 estimates that cells with a large perimeter are differentiated cells. As a result, the DB creation unit 24 associates information indicating that the cell is differentiated with a large perimeter in the morphological information and stores it. FIG. 9 shows the feature information of cells with respect to morphological information stored in the DB 5 according to this embodiment. News 9 is a diagram showing an example. As shown in Fig. 9, the DB creating unit 24 associates shape characteristics (for example, a large circumferential length) with cell characteristic information indicating that the characteristic is differentiation, and stores the information.

[0060] The control device 2 may learn the gene characteristics shown in FIG. 8 and the shape characteristics shown in FIG. Furthermore, when extracting feature amounts from the information stored in the DB5, the control device 2 may extract feature amounts by subjecting the stored information to machine learning rather than calculating correlation coefficients.

[0061] [DB5 creation process] Next, an example of the DB5 creation process procedure will be described. Fig. 10 is a flowchart of the DB5 creation process according to this embodiment. The operator places an suction tip 324 according to the suction purpose on the tip rack 325. For example, when suctioning cellular components, a nanospray tip is placed, and when suctioning a single cell, a normal suction tip is placed.

[0062] (Step S1) An operator prepares a cell sample (e.g., cancer cells). Next, the operator places the sample in a cell culture well plate 5. Next, the operator sets the cell culture well plate 5 on the XY stage 3213 of the imaging and suction device 3. The imaging and suction device 3 detects that the cell culture well plate 5 has been set on the XY stage 3213. Note that the imaging and suction device 3 may detect that the sample has been set based on, for example, the result of the operator operating the operation unit 21 of the control device 2, may detect it from an image captured by the imaging unit 3211, or may detect it from a sensor provided in the imaging and suction unit 32.

[0063] (Step S2) The operator adds a candidate compound (reagent) to the prepared cell sample. The operator may perform, for example, fluorescent staining, as necessary. The imaging and aspirating device 3 detects that the reagent has been added. The imaging and aspirating device 3 may detect that the reagent has been added based on, for example, the result of the operator operating the operation unit 21 of the control device 2, or may detect it by a sensor provided in the imaging and aspirating unit 32.

[0064] (Step S3) The imaging and suction device 3, under the control of the control device 2, images the entire sample.

[0065] (Step S4) The image analysis unit 33 of the photographing and suction device 3 performs image processing on the photographed image to obtain morphological information.

[0066] (Step S5) The aspirated cell selection unit 23 of the control device 2 determines whether or not there are cells or tissues to be aspirated based on the morphological information. The aspirated cell selection unit 23 may transmit an instruction to the imaging and aspirating unit 32 to take a magnified image of the region to be aspirated, and determine whether or not there are cells or tissues to be aspirated based on the morphological information contained in the result of the imaging and aspirating unit 32 taking the magnified image and processing the image. When the aspirated cell selection unit 23 determines that there are cells or tissues to be aspirated (Step S5; YES), it proceeds to the process of Step S6. When the aspirated cell selection unit 23 determines that there are no cells to be aspirated (Step S5; NO), it returns to the process of Step S1.

[0067] (Step S6) The aspirated cell selection unit 23 determines the cell or tissue to be aspirated. Then, the aspirated cell selection unit 23 outputs an aspirating instruction to aspirate the determined cell or tissue to be aspirated to the photographing and aspirating device 3. Then, the photographing and aspirating device 3 aspirates the cell or tissue to be aspirated.

[0068] (Step S7) Control device 7 outputs an analysis instruction to analyze the aspirated cells or tissue to analysis device 4. Subsequently, analysis device 4 performs, for example, genetic analysis on the aspirated cells or tissue to obtain genetic information.

[0069] (Step S8) The DB creation unit 24 associates the acquired morphological information with the genetic information and stores them in the DB, thereby updating the information in the DB.

[0070] (Step S9) The feature extraction unit 25 calculates a correlation coefficient from DB5 and extracts the feature. Then, the feature extraction unit 25 stores the extracted feature in association with the information stored in DB5. Next, if there is a strong correlation in the calculated correlation coefficient, the feature extraction unit 25 acquires cell feature information indicating the cell state (e.g., differentiated, undifferentiated) by, for example, referring to DB5, and stores the acquired cell feature information in DB5 in association with morphological information.

[0071] [Example of creating a DB for ES cells] Here, an example of creating a DB for ES cells (Embryonic Stem Cells) will be described. First, the operator sets ES cells (one type of cell) as a sample in the cell culture well plate 5. Next, the operator adds a differentiation-inducing reagent (multiple types of reagent). Next, the imaging and suction device 3 images the ES cells. Next, the image analysis unit 33 obtains morphological information by image analysis.

[0072] Next, the aspirated cell selection unit 23 selects a cell to be aspirated. Next, the photographing and aspirating device 3 aspirates the selected one cell. Next, the analysis device 4 acquires genetic information by genetic analysis. Next, the DB creation unit 24 of the control device 2 updates the DB 5 by associating the morphological information and the genetic information for each cell. Next, the feature extraction unit 25 of the control device 2 calculates a correlation coefficient for each parameter of the morphological information and the genetic information, and stores the calculated correlation coefficient as a feature in association with the information stored in the DB5.

[0073] [Example of sample evaluation procedure] Next, an example of an evaluation procedure for evaluating a sample using the DB of this embodiment will be described. FIG. 11 is a flowchart of an evaluation procedure for evaluating a sample using the DB according to this embodiment.

[0074] (Step S101) The imaging and suction device 3 detects that the cell culture well plate 5 has been set on the XY stage 3213, similarly to step S1 (FIG. 10).

[0075] (Step S102) The operator adds a candidate compound (reagent) to the prepared cell sample. The imaging and aspirating device 3 detects that the reagent has been added, similarly to step S2 (FIG. 10).

[0076] (Step S103) The imaging and suction device 3, under the control of the control device 2, images the entire sample.

[0077] (Step S104) The image analysis unit 33 of the photographing and suction device 3 performs image processing on the photographed image to obtain morphological information.

[0078] (Step S105) The estimation unit 26 estimates the state of the cell (for example, differentiated, undifferentiated) by using the morphological information and referring to the information stored in the DB 5. Subsequently, the estimation unit 26 causes the display unit 22 to display the estimation result.

[0079] As described above, in this embodiment, the image of the sample is analyzed to obtain morphological information, and one cell is aspirated and genetically analyzed to obtain genetic information. In this embodiment, the morphological information and genetic information are stored in DB5 in association with each other, and the feature amount (e.g., correlation coefficient) of the information stored in DB5 is extracted. In this embodiment, the extracted feature amount is stored in association with the information stored in DB5.

[0080] As a result, according to this embodiment, the state of the cells (e.g., differentiated, undifferentiated) can be estimated by referring to the DB (database) created in this way using morphological information extracted from the image of the sample. That is, according to this embodiment, the state of the cells can be estimated based on the captured image without performing analysis such as genetic analysis on the cells contained in the sample with the analysis device 4. Furthermore, in the conventional technology, an experienced person judges the evaluation of the cells by looking at the captured image. In contrast, according to this embodiment, the cell or tissue evaluation is performed by the cell database creation system, which estimates the state of the cells based on the captured image, so that the evaluation can be performed without an experienced person.

[0081] In addition, in the conventional technology, for example, a floating cell group whose morphology has changed due to a stimulus is collected, making it difficult to evaluate a single cell in an adherent state. In contrast, according to the present embodiment, the state of the cells or tissues contained in the cell sample is estimated from an image of the cell sample, making it possible to evaluate a single cell in an adherent state.

[0082] Here, an example of an evaluation method for the comparative example will be described. It is known that when undifferentiated ES cells are cultured, their undifferentiated state is not maintained, and some cells end up differentiating. Experienced workers predict which cells will be differentiated from their appearance, and maintain the undifferentiated state of the cells by removing cells that are thought to be differentiated from the incubator. However, the relationship between morphological changes at the single cell level and the undifferentiated state has not been clarified. Therefore, for a device to remove differentiated cells, a method could be considered in which an experienced worker uses machine learning to teach the device the morphology of differentiated cells, allowing it to separate differentiated and undifferentiated cells. In this case, it is difficult to determine whether the classification of differentiated and undifferentiated that the experienced worker has taught is correct.

[0083] In contrast, according to the present embodiment, the relationship between morphological information and genetic information is calculated and associated by a correlation coefficient, and stored in DB5. By referring to the DB using morphological information obtained from an image of a sample, it is possible to find morphological characteristics that are specifically identified in differentiated cells.

[0084] <Additional Notes> (1) an imaging unit for imaging a sample in which a candidate drug has been added to a cell sample; a database for storing information about cells contained in the cell sample; An aspirator that aspirates the cells; an analysis device for analyzing the aspirated cells; an image analysis unit that performs image processing on the captured image; a control device that acquires morphological information on the shapes of cells contained in the cell sample based on a result of the image processing, selects one cell to be aspirated based on the morphological information, aspirates the selected one cell using the aspirator, analyzes the aspirated one cell using the analyzer, extracts feature amounts of the molecular information and the morphological information acquired based on the analysis result, and stores the morphological information, the molecular information, and the feature amounts in the database in association with each other for each cell; A cell database creation system comprising: (2) The morphological information is The information includes information indicating the position of a cell or the position of a nucleus, and is at least one of a cell area, a nucleus area, a cell circumference, a nucleus circumference, a cell major axis, a nucleus major axis, a cell minor axis, a nucleus minor axis, a cell apex ratio, a nucleus apex ratio, etc. A cell database creation system according to (1). (3) the molecular information, At least one of gene information, protein information, peptide information, amino acid information, lipid information, carbohydrate information, mass information, etc. A cell database creation system according to (1) or (2). (4) The molecular information is It is genetic information, The feature amount is A correlation coefficient between the morphological information and the genetic information. A cell database creation system according to (1) or (2). (5) The control device the sample is photographed, and the morphological information obtained based on the image processing results is used to estimate the state of the cells contained in the sample with reference to the database; A cell database creation system according to any one of (1) to (4). (6) a procedure in which the imaging unit images a sample in which a candidate drug is added to a cell sample; A procedure in which an image analysis unit performs image processing on a captured image; a step of a control device acquiring morphological information on the shapes of cells contained in the cell sample based on the image processing result, and selecting one cell to be aspirated based on the morphological information; an aspirating unit aspirating the selected one cell; A procedure in which an analysis device analyzes the one aspirated cell; a step of the control device extracting feature amounts of the molecular information and the morphological information obtained based on the analysis result; a step of storing, by the control device, the morphological information, the molecular information, and the feature amount for each of the cells in a database in association with each other; A method for creating a cell database comprising the steps of:

[0085] <Second embodiment> In the second embodiment, an example in which a drug discovery screening system 1 performs drug discovery screening will be described.

[0086] [Terminology used in drug discovery screening] First, we will explain the terminology used in screening for drug development evaluation. Drug efficacy assessment is a process of determining whether or not a drug added to a cell sample is effective. Morphological evaluation is a process of processing a photographed image of a sample and evaluating the shape of the cells based on the results of the image processing. Structural modification is a process of changing part of the structure of the added drug. Dynamics confirmation is a process of confirming the effect of a drug on cells, such as whether it theoretically has no adverse effects on normal cells, based on genetic analysis, etc. Physical property evaluation is a process of evaluating whether or not there are any physical problems, such as the tendency of a compound to be decomposed and turned into a toxic substance. Toxicity evaluation is a process of administering a drug multiple times to evaluate whether or not it accumulates in the body, i.e., whether or not it is toxic. In this embodiment, a region containing cells or tissues in a state where the effect of a drug is not observed is called a specific region. Alternatively, the specific region may be a region containing special cells (e.g., cells having multiple nuclei).

[0087] [Outline of the second embodiment] Next, an outline of this embodiment will be described. In general drug discovery screening, the process is carried out in the following order: morphological evaluation, efficacy evaluation, structural modification, kinetic confirmation, physical property evaluation, and toxicity evaluation. However, in general drug discovery screening, there is a possibility that, for example, toxic compounds may remain as candidates until the evaluation immediately before clinical trials. A lot of man-hours and costs are spent on testing up to toxicity evaluation. For this reason, if the development of a drug using the compound is discontinued or the drug discovery screening process has to be redone due to toxicity testing, the developer will suffer a large loss. For this reason, in this embodiment, after efficacy evaluation, cells in a specific state are aspirated during the drug discovery screening process, and the aspirated cells are analyzed to estimate the kinetics and toxicity. As a result, in this embodiment, it is determined whether or not to proceed with the drug discovery screening process before completing the drug discovery screening process, thereby improving the efficiency of drug discovery screening.

[0088] [Overview of Drug Discovery Screening System 1 and overview of each device] The configuration of a drug discovery screening system 1 according to this embodiment is similar to that of the drug discovery screening system 1 according to the first embodiment (FIGS. 1 and 2). The drug discovery screening system 1 takes images of a sample in which a candidate drug has been added to a cell sample during the drug discovery screening process, analyzes the taken images using information stored in DB5, aspirates cells or tissues, and analyzes the aspirated cells or tissues. The drug discovery screening system 1 uses information stored in DB5 to analyze the aspirated cells or tissues, and determines whether or not to proceed with the drug discovery screening process based on the results. Note that the objects to be aspirated are not limited to cells or tissues, and may include surrounding compounds, culture fluid, etc.

[0089] In this embodiment, a specimen in which a candidate drug is added to a sample of a plurality of cells 51 is placed on the cell culture well plate 5. The specimen may contain a cell culture solution 52. In the following description, it is assumed that a staining agent is added to the specimen to confirm the effect of the drug.

[0090] The imaging and suction device 3 captures an image of the entire inside of the cell culture well plate 5 placed on the XY stage 3213 or an image of a specific region in response to an imaging instruction from the control device 2. The imaging and suction device 3 performs image analysis on the captured image and outputs the image analysis results to the control device 2. The imaging and suction device 3 aspirates the cells to be aspirated in response to an aspiration instruction from the control device 2. The image analysis results include information indicating the captured image and the shape, size, position, etc. of each cell contained in the image.

[0091] The analysis device 4 performs analysis such as genetic analysis on the cells or tissues aspirated by the imaging and aspirating device 3 and contained in the aspirating tip 324 stored in the sample rack 326. The analysis method will be described later. The analysis device 4 outputs the analysis results to the control device 2.

[0092] As in the first embodiment, DB5 stores morphological information and genetic information for each analyzed cell in association with each other. DB5 stores morphological information and genetic information in association with a correlation coefficient between the morphological information and the genetic information. DB5 stores information indicating whether the cell is differentiated or undifferentiated in association with the morphological information. DB5 stores each gene name in association with the characteristics of the cell having the gene, as described later.

[0093] When the cell culture well plate 5 is set on the photographing and aspirating device 3, the control device 2 controls the photographing and aspirating device 3 so that the entire sample is photographed. The control device 2 acquires the image processing results for the entire sample by the photographing and aspirating device 3. The control device 2 determines whether or not a unique region is present in the image analysis results by referring to the information stored in the DB5. If a unique region is present, the control device 2 displays on the display unit 22 that drug discovery screening should be continued. If a unique region is present, the control device 2 estimates the position of the cells or tissue to be aspirated based on the position of the region. The control device 2 outputs an aspirating instruction to the photographing and aspirating device 3 to aspirate the cells or tissue to be aspirated based on the determined position of the cells or tissue.

[0094] [Functions and operation of the imaging and suction device 3] Next, the function and operation of the photographing and suction device 3 will be described. First, for example, an operator sets the cell culture well plate 5 on the XY stage 3213. The imaging and suction device 3 outputs to the control device 2 information indicating that the cell culture well plate 5 has been set.

[0095] Next, the photographing and suctioning unit 32 photographs the entire sample in the xy plane of the cell culture well plate 5 in response to a photographing instruction from the control device 2. The photographing and suctioning unit 32 outputs the photographed image to the image analysis unit 33. The image analysis unit 33 performs image analysis on the photographed image to analyze the shape of the cells contained in the image. The photographing and suctioning device 3 outputs the image analysis result to the control device 2. The image processing result includes position information of the cells or the positions of the cells. The position information is, for example, xy coordinate values ​​in the xy plane with the center of the cell culture well plate 5 as the origin.

[0096] When a unique region is present, the imaging and suction unit 32 moves the XY stage 3213 in the xy plane in response to an imaging instruction from the control device 2 to image the unique region. When imaging the unique region, the imaging and suction unit 32 images the unique region at a higher magnification than when imaging the entire sample. The imaging and suction unit 32 sets the magnification when imaging the entire sample to, for example, 10 times, and sets the magnification when imaging the unique region to, for example, 100 times. The image analysis unit 33 performs image analysis on the captured image to analyze the shape of the cells contained in the image (the area of ​​the cytoplasm, the area of ​​the nucleus, the circularity of the nucleus, etc.). The imaging and suction device 3 outputs the image analysis results to the control device 2.

[0097] When there are cells or tissues to be aspirated, the imaging and aspirating unit 32 mounts one of the multiple aspirating tips 324 stored in the tip rack 325 to the aspirating unit 322 in response to an aspirating command from the control device 2. Next, the imaging and aspirating unit 32 moves the aspirating unit 322 and the XYZ stage 323 in response to an aspirating command from the control device 2 to aspirate the desired cells or tissues.

[0098] Next, the imaging and aspirating unit 32 stores the aspirating tip 324 that has aspirated the cells or tissue in a predetermined position in the sample rack 326. Next, the imaging and aspirating unit 32 outputs information indicating that the aspirating tip 324 that has aspirated the cells or tissue has been stored in the sample rack 326 to the analysis device 4.

[0099] [Functions and operations of image analysis unit 33] Next, the function and operation of the image analysis unit 33 will be described.

[0100] First, the processing for the image of the entire sample will be described. The image analysis unit 33 acquires an image of the entire sample output by the imaging and suction unit 32. The image analysis unit 33 then performs image processing on the acquired image of the entire sample. The image processing includes, for example, edge detection processing, feature amount detection processing, clustering processing, and the like. The image of the entire sample is an image of a sample in which a candidate drug is added to a cell sample and the sample is stained with, for example, a dye to confirm the effect of the drug. The image analysis unit 33 outputs the image processing result to the control device 2.

[0101] Next, processing for an image of a unique region will be described. The image analysis unit 33 acquires an image of the unique region output by the imaging and suction unit 32. The image analysis unit 33 then performs image processing on the acquired image of the unique region. The image processing result includes position information of the cells or the positions of the cells. The image analysis unit 33 outputs the image processing result on the image of the unique region to the control device 2. When there are multiple unique regions, the image analysis unit 33 may select at least one unique region from the multiple unique regions and output the position of the cells or tissue in the selected unique region to the control device 2.

[0102] [Functions and operation of analysis device 4] Next, the functions and operations of the analysis device 4 will be described. The analysis device 4 stores information such as genetic information, components, mass, etc. for each cell or tissue.

[0103] The analysis device 4 performs, for example, genetic analysis on the cells or tissues aspirated by the imaging and aspirating device 3. The analysis device 4 estimates pharmacokinetics and toxicity based on the results of the genetic analysis and the stored information. If the analysis device 4 estimates that the added drug has a problem with pharmacokinetics or toxicity as a result of estimating pharmacokinetics and toxicity, the analysis device 4 outputs information to the control device 2 prompting the suspension of the drug discovery screening process using the added drug (compound). If the analysis device 4 estimates that the added drug has no problem with pharmacokinetics and toxicity as a result of estimating pharmacokinetics and toxicity, the analysis device 4 outputs information to the control device 2 prompting the continuation of the drug discovery screening process. The method of analyzing cells or tissues will be described later.

[0104] [Functions and operations of control device 2] Next, the function and operation of the control device 2 will be described. The operation unit 21 detects the result of the operation performed by the operator, and outputs the detected operation result to the control unit 27. The operation result includes, for example, information indicating the start of a drug discovery screening process, setting of the cell culture well plate 5 on the XY stage 3213, and the like.

[0105] The control unit 27 outputs an instruction to the imaging and suction device 3 to image the entire sample, and acquires the image that has been captured and the image processing results for the captured image. The imaging conditions (e.g., the designation of the optical system such as confocal, epifluorescence, phase contrast, etc., the wavelength setting, the imaging interval, the total imaging time, etc.) may be input by the operator by operating the operation unit 21, or may be stored in the control unit 27 in advance.

[0106] The control unit 27 outputs an image capturing instruction to the image capturing and aspirating device 3 to capture an image of the specific region based on the information indicating the cell or the position of the cell in a state where the effect of the drug is not manifested, output by the aspirated cell selecting unit 23. The image capturing instruction includes information indicating the position of the specific region to be captured.

[0107] The control unit 27 outputs a suction instruction to the photographing and aspirating device 3 to aspirate the desired cell or tissue based on the position information of the cell or tissue to be aspirated outputted by the photographing and aspirating device 3. The control unit 27 receives the analysis result of the aspirated cell or tissue outputted by the analysis device 4, and causes the display unit 22 to display the received analysis result.

[0108] Based on the image processing results for the image of the entire sample and the information stored in DB5, the aspirated cell selection unit 23 determines whether the sample contains cells or tissues in a state where the effect of the drug is being exerted (cells in a first state) and whether the sample contains cells or tissues in a state where the effect of the drug is not being exerted (cells in a second state). The aspirated cell selection unit 23 outputs information indicating the positions of cells or cells in a state where the effect of the drug is not being exerted to the control unit 27. Note that a method for distinguishing between cells or tissues in a state where the effect of the drug is being exerted (cells in a first state) and cells or tissues in a state where the effect of the drug is not being exerted (cells in a second state) will be described later.

[0109] The aspirated cell selection unit 23 determines whether there are cells or tissues to be aspirated based on the image processing result for the image of the specific region and the information stored in the DB 5. When the aspirated cell selection unit 23 determines that there are cells or tissues to be aspirated, it determines the cells or tissues to be aspirated. The aspirated cell selection unit 23 outputs position information of the determined cells or tissues to be aspirated to the control unit 27.

[0110] The estimation unit 26 refers to the analysis results output by the analysis device 4 and the information stored in the DB 5 to determine whether the kinetics and toxicity of the added compound can be improved by structural modification. The estimation unit 26 determines whether there is a problem with the kinetics based on the results of the kinetic confirmation performed by the analysis device 4. The estimation unit 26 determines whether there is a problem with the toxicity based on the results of the physical property determination performed by the analysis device 4.

[0111] [Aspiration cell determination] Next, a description will be given of an example of a method for determining the aspirated cells or tissues performed by the control device 2 and the imaging and aspirating device 3. In the following description, an example will be described in which the subject of aspirating and analyzing is cells.

[0112] The imaging and suction unit 32 images the entire sample in response to an imaging instruction output by the control device 2, as shown in FIG.

[0113] The image analysis unit 33 performs image processing such as clustering on the entire image of the photographed material. The image analysis unit 33 outputs the image processing result to the control device 2.

[0114] The aspirated cell selection unit 23 refers to the information stored in the DB5 based on the image processing result and determines whether there is a region of cells in a state where the effect of the drug is being exerted or a region of cells in a state where the effect of the drug is not being exerted. The aspirated cell selection unit 23 may be configured to determine, for example, based on the shape or state of the cells, a region in which cell differentiation has stopped due to the drug as a region of cells in a state where the effect of the drug is being exerted. The aspirated cell selection unit 23 may also be configured to determine, for example, based on the shape or state of the cells, a region in which cell differentiation has not stopped due to the drug as a region of cells in a state where the effect of the drug is not being exerted.

[0115] When it is determined that there is no region of cells in which the drug's effect is being exerted, the aspirated cell selection unit 23 determines that the drug's effect is not being exerted. Alternatively, when the area of ​​the region of cells in which the drug's effect is being exerted is less than a threshold value with respect to the value of the entire area of ​​the sample, the aspirated cell selection unit 23 determines that the drug's effect is not being exerted. Alternatively, when the area of ​​the region of cells in which the drug's effect is being exerted is equal to or greater than a threshold value with respect to the value of the entire area of ​​the sample, the aspirated cell selection unit 23 determines that the drug's effect is being exerted.

[0116] When the area of ​​the cell region where the effect of the drug is being exerted is equal to or greater than a threshold value relative to the area of ​​the entire sample, the aspirated cell selection unit 23 outputs the central position of the nucleus of the cell included in the cell region where the effect of the drug is not being exerted to the control unit 27. When there are multiple cell regions where the effect of the drug is not being exerted, the aspirated cell selection unit 23 outputs the central position of the nucleus of the cell included in the cell region where the effect of the drug is not being exerted for each of the multiple regions to the control unit 27. The cells present in the cell region where the effect of the drug is being exerted are cells in the first state (cells of major proportions). The cells present in the cell region where the effect of the drug is not being exerted are cells in the second state (cells of minor proportions).

[0117] In response to an instruction to photograph from the control device 2, the photographing and suction device 3 photographs the peculiar region at a magnification higher than that used to photograph the entire sample, as shown in Fig. 4. In response to an instruction to photograph from the control device 2, the photographing and suction device 3 also photographs the region g112 in Fig. 3.

[0118] The image analysis unit 33 performs image processing on the captured image. Through this image processing, the image analysis unit 33 obtains the position of the cell (center coordinates (x1, y1) of the nucleus) and the lengths of the long and short sides in the xy plane. In addition, as described in the above-mentioned JP 2019-41691 A, the image analysis unit 33 obtains the height of the nucleus by moving the objective lens of the photographing unit 3211 of the photographing and suction device 3 in the z direction and photographing it. The image analysis unit 33 performs the same processing on the region of the symbol g112 in FIG. 3. The image analysis unit 33 outputs the image analysis result including the information of the cells included in the region of the cells in which the effect of the drug is not observed (center coordinates of the nucleus, the lengths of the long and short sides in the xy plane, and the height in the z direction) to the control device 2.

[0119] The aspirated cell selection unit 23 selects cells to be aspirated based on the image analysis results output by the image analysis unit 33 and with reference to the information stored in the DB5. When there are two specific regions as shown in FIG. 3, the aspirated cell selection unit 23 may select cells to be aspirated from either one of the regions, or may select cells to be aspirated from both regions. In this manner, the aspirated cell selection unit 23 selects at least one cell to be aspirated. When there are multiple specific regions, the aspirated cell selection unit 23 may select cells to be aspirated from multiple specific regions based on, for example, the shape of the nucleus, the size (area) of the nucleus, the position of the nucleus, the cell cycle state of the cell, and the like.

[0120] [Drug discovery screening process] Next, an example of a drug discovery screening process procedure will be described with reference to Figs. 12 to 14. Fig. 12 is a schematic flow chart of the drug discovery screening process according to this embodiment. Figs. 13 and 14 are flow charts of the drug discovery screening process according to this embodiment. In addition, when screening, the operator places the suction tip 324 according to the suction purpose on the tip rack 325. For example, when suctioning cellular components, a nanospray tip is placed, and when suctioning one cell, a normal suction tip is placed. In addition, when the size of the cell is unknown, suction tips 324 of multiple sizes may be placed on the tip rack 325 in advance. Then, based on the image processing result, the imaging and suction device 3 may select the suction tip 324 according to the control of the control device 2. In addition, the cell sample to be evaluated is, for example, a cancer cell.

[0121] (Steps S101 to S105) The drug discovery screening system 1 performs the processes of steps S101 to S105 in FIG. (Step S200) The drug discovery screening system 1 performs screening processing (steps S201 to S217 in FIGS. 12 and 13).

[0122] (Step S201) The aspirated cell selection unit 23 performs a drug efficacy judgment based on the state of the cells. If the drug efficacy judgment result indicates that the drug is effective (Step S201; Effective), the aspirated cell selection unit 23 proceeds to processing in step S203. If the drug efficacy judgment result indicates that the drug is ineffective (Step S201; Ineffective), the aspirated cell selection unit 23 proceeds to processing in step S202.

[0123] (Step S202) The control unit 27 causes information indicating that the compound determined to be problematic is to be excluded to be displayed on the display unit 22. Subsequently, the control unit 27 returns the process to step S101.

[0124] (Step S203) The aspirated cell selection unit 23 refers to the information stored in the DB5 based on the image processing results for the image of the entire sample, and determines whether the sample contains cells or tissues in which the drug effect is being exerted, or whether the sample contains cells or tissues in which the drug effect is not being exerted. If the aspirated cell selection unit 23 subsequently determines that all cells have the same morphology, it proceeds to the process of step S210 (FIG. 14). If the aspirated cell selection unit 23 determines that the sample contains cells or tissues in which the drug effect is not being exerted, that is, if it determines that some cells have different morphologies, it proceeds to the process of step S204.

[0125] (Step S204) The imaging and suction unit 32, in response to an imaging instruction from the control device 2, captures an image of the unique region.

[0126] (Step S205) The image analysis unit 33 performs image processing on the captured image and outputs the image analysis result to the control device 2.

[0127] (Step S206) The aspirated cell selection unit 23 determines the cells or tissues to be aspirated based on the image processing result and the information stored in the DB 5. Next, the control unit 27 generates an aspirating instruction based on the cells or tissues to be aspirated determined by the aspirated cell selection unit 23, and outputs the generated aspirating instruction to the imaging and aspirating device 3.

[0128] (Step S207) In response to a suction instruction from the control device 2, the imaging and suction unit 32 suctions the desired cell or tissue.

[0129] (Step S208) Analysis device 4 performs analysis (for example, genetic analysis) on the sucked cells or tissue. Analysis device 4 outputs the analysis results to control device 2.

[0130] (Step S209) The estimation unit 26 refers to the analysis results output by the analysis device 4 and the information stored in the DB 5 to determine whether the kinetics and toxicity of the added compound can be improved by structural modification. If the estimation unit 26 determines that the kinetics and toxicity can be improved by structural modification (Step S209; improvement possible), the estimation unit 26 proceeds to processing in step S210. If the estimation unit 26 determines that the kinetics and toxicity cannot be improved by structural modification (Step S209; improvement not possible), the estimation unit 26 proceeds to processing in step S202 (FIG. 13).

[0131] (Step S210) The operator performs structural modification on the compound used in step S101. Then, the operator adds the structurally modified compound to the cell sample prepared in step S101. Next, the operator puts the sample into the cell culture well plate 5. The operator performs, for example, fluorescent staining, as necessary. Next, the operator removes the cell culture well plate 5 used in steps S101 to S105 and S201 to S209 from the XY stage 3213 of the imaging and suction device 3. Next, the operator sets the cell culture well plate 5 on which the specimen of the cell sample to which the structurally modified compound has been added is placed, on the XY stage 3213 of the imaging and suction device 3. The imaging and suction device 3 detects that the cell culture well plate 5 has been set on the XY stage 3213 of the imaging and suction device 3.

[0132] (Step S211) The analysis device 4 performs, for example, genetic analysis on the cells contained in the sample to check the behavior. During the behavior check, the control device 2 controls the imaging and suction device 3 to suction cells or tissues from the sample.

[0133] (Step S212) The estimation unit 26 determines whether or not there is a problem with the movement, based on the result of the movement confirmation performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with the movement (step S212; no problem), the estimation unit 26 proceeds to the process of step S213. If the estimation unit 26 determines that there is a problem with the movement (step S212; problem), the estimation unit 26 proceeds to the process of step S202 (FIG. 13).

[0134] (Step S213) The analysis device 4 evaluates the physical properties of the added compound.

[0135] (Step S214) The estimation unit 26 determines whether or not there is a problem with the physical properties based on the result of the physical property evaluation performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with the physical properties (Step S214; No problem), the estimation unit 26 proceeds to processing of Step S215. If the estimation unit 26 determines that there is a problem with the physical properties (Step S214; Problem present), the estimation unit 26 proceeds to processing of Step S202 (FIG. 13).

[0136] (Step S215) The analysis device 4 performs toxicity evaluation.

[0137] (Step S216) The estimation unit 26 determines whether or not there is a problem with toxicity based on the result of the physical property determination performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with toxicity (Step S216; No problem), the estimation unit 26 proceeds to processing of Step S217. If the estimation unit 26 determines that there is a problem with toxicity (Step S216; Problem), the estimation unit 26 proceeds to processing of Step S202 (FIG. 13).

[0138] (Step S217) The control unit 27 causes the display unit 22 to display information indicating that there were no problems in the screening process. In response to this, clinical trials are conducted on humans using the drug (compound). After the process, the drug discovery screening process is terminated.

[0139] As an example of step S209, if toxicity can be alleviated by a method such as combined use with a drug that suppresses toxicity based on toxicity evaluation by genetic analysis, the process proceeds to structural modification in step S210. For example, if there is an effect of inducing inflammation, a drug with an anti-inflammatory effect is used in combination. If there is no method to alleviate toxicity, the drug may be removed from the candidate drugs.

[0140] [How to select cells to aspirate] Next, an example of a method for selecting cells to be sucked when there are a plurality of unique regions will be described. FIG. 15 is a flowchart of the process of selecting cells to be sucked according to this embodiment.

[0141] (Step S301) The aspirated cell selection unit 23 makes a list of morphological information of cells in each unique region and stores the list in the DB5.

[0142] (Step S302) The aspirated cell selection unit 23 selects at least one item from among a plurality of items of morphological information.

[0143] (Step S303) The aspirated cell selecting unit 23 sorts the list of morphological information for the selected item.

[0144] (Step S304) The aspirated cell selection unit 23 selects a predetermined number of cells based on the sorting result.

[0145] Fig. 16 is a diagram showing an example of morphological information according to this embodiment. The morphological information is, for example, the area of ​​the cytoplasm, the area of ​​the nucleus, the circularity of the cytoplasm, the kurtosis of the cytoplasm, etc. As shown in Fig. 16, DB5 stores morphological information in association with a number. Note that the example shown in Fig. 16 is just an example, and the morphological information is not limited to this.

[0146] Furthermore, the aspirated cell selection unit 23 may select cells or tissues to be aspirated in any one of the following ways I to III. I. When one parameter of the cells to be aspirated is determined The aspirated cell selection unit 23 selects, for example, the nucleus area from among the items (parameters). Then, the aspirated cell selection unit 23 sorts the list of morphological information by the nucleus area and selects, for example, the top 10 cells.

[0147] II. When two parameters of the cells to be aspirated are determined The aspirated cell selection unit 23 selects, for example, cytoplasmic circularity and nuclear area from among the items (parameters).Then, the aspirated cell selection unit 23 selects cells with a cytoplasmic circularity of 0.8 or less, sorts the list of morphological information of the selected cells by nuclear area, and selects, for example, the top 10 cells.

[0148] III. When the parameters of the cells to be aspirated are unknown The aspirated cell selection unit 23 selects, for example, nucleus area from among the items (parameters). Then, the aspirated cell selection unit 23 sorts the list of morphological information by nucleus area, and selects, for example, cells ranked 1st, 10th, 20th, .... This provides randomness to the selection of cells. Note that the aspirated cell selection unit 23 may randomly select 10 cells. By randomly aspirating and analyzing cells or tissues in this way, it may be possible to detect unexpected responses that are not dependent on known parameters.

[0149] [Analysis target, analysis method] Here, an example of a subject of analysis and an example of an analysis method performed by the analysis device 4 will be described. First, an example of a subject of analysis will be described. The analysis device 4 performs analysis, for example, of compounds possessed or produced by the acquired cells. The analysis device 4 performs analysis, for example, of compounds produced by the acquired surrounding cells. The analysis device 4 performs analysis, for example, of compounds added to the culture supernatant of the acquired cells. The analysis device 4 performs analysis, for example, of compounds administered to the individual of the acquired cells or ingested by the individual.

[0150] The analysis targets are organic or inorganic compounds contained in the compound. The analysis targets are proteins (including antibodies, cytokines, enzymes, etc.), peptides, amino acids, lipids, carbohydrates, DNA, RNA (including mRNA, ncRNA, rRNA, tRNA, etc.) contained in the organic compound, candidate compounds to be screened, etc. ncRNA includes lncRNA, siRNA, miRNA, piRNA, etc. The analysis targets are salts, metal ions, etc. contained in the inorganic compound.

[0151] Next, an example of an analysis method will be described. Note that control unit 27 selects an appropriate device for analysis from analysis device 4-1, analysis device 4-2, ... according to the type of analysis. The analysis device 4 performs at least one of the following analyses: mass spectrometry, NMR (Nuclear Magnetic Resonance), liquid chromatography, Raman spectroscopy, infrared spectroscopy, electrophoresis, and elemental analysis. Mass spectrometry includes an ionization method. Ionization methods include EI (electron ionization), CI (chemical ionization), FAB (fast atom bombardment), ESI (electrospray ionization), and MALDI (matrix-assisted laser desorption ionization). Mass spectrometry may also be performed by connecting two mass spectrometers (MS) in series and using an apparatus having a collision activation chamber between them.

[0152] In addition, the analysis device 4 uses techniques such as NGS (next generation sequencer), qPCR (quantitative polymerase chain reaction), microarray, digital PCR, sequencer, etc., in the analysis of DNA and RNA. In addition, a reverse transcription process may be included in the analysis of RNA. In addition, the introduction method for mass spectrometry may be direct introduction or a method connected to liquid chromatography.

[0153] In the conventional technology, multiple evaluation and confirmation processes were performed in sequence, resulting in a large loss of labor and costs when a problem was discovered in a toxicity test, for example.In addition, in the conventional technology, evaluation was performed on the average of multiple cells (for example, by grinding the cells for evaluation), so there was still the possibility that some cells that were ineffective against the drug could have a large impact on the patient's prognosis.

[0154] In contrast to this, in the present embodiment, after the drug efficacy assessment is performed during the drug discovery screening process, unique cells (cells in the second state, minor population cells) are sucked and analyzed.

[0155] As a result, according to this embodiment, by aspirating cells during the drug discovery screening process and performing, for example, genetic analysis, it is possible to determine whether or not toxicity can be alleviated by structural modification, such as combined use with a drug that suppresses toxicity. In this embodiment, it is possible to estimate that a drug that has been effective in this way cannot be improved by structural modification using aspirated cells before structural modification, dynamics confirmation, physical property evaluation, or toxicity evaluation is performed. In this embodiment, when it is estimated that the drug (compound) cannot be improved by structural modification, the drug (compound) is excluded and the subsequent drug discovery screening process is not performed with the compound. As a result, according to this embodiment, the drug discovery screening period can be reduced. Furthermore, according to this embodiment, individual cells can be aspirated and analyzed during the drug discovery screening process, so drug discovery screening can be performed even when multiple cell samples are mixed. Furthermore, according to this embodiment, individual cells can be aspirated and analyzed during the drug discovery screening process, so that problems with dynamics and toxicity can be found early without missing rare reactions of cells and tissues. Furthermore, according to this embodiment, individual cells are aspirated and analyzed during the conventional drug discovery screening process, so it is possible to respond without significantly changing the conventional drug discovery screening process. Furthermore, according to this embodiment, for cells in the second state (cells of a minor proportion), processing such as structural modification can be carried out in parallel with processing such as image processing, suction, and analysis, thereby reducing the drug discovery screening period.

[0156] In the above example, the molecular analysis in step S208 of Fig. 14 is performed as gene analysis, but the present invention is not limited to this example. The molecular analysis may be, for example, an analysis method such as mass spectrometry or Western blotting.

[0157] Furthermore, after obtaining the cells in step S207 in FIG. 14, instead of analyzing the sample, it is also possible to culture a single cell and perform another test after the cell has grown.

[0158] Furthermore, although an example of cells has been described as an object to which a compound (drug) is added, the object to which a compound is added may also be a spheroid (cell aggregate), tissue, microorganism, plant, or the like.

[0159] In addition to screening to evaluate drug efficacy, the method of this embodiment can also be used to remove cells in the second state (minor population cells) when culturing stem cells or inducing differentiation, to investigate the cause of failure to induce differentiation as expected, and to confirm the cause.

[0160] Furthermore, the subject of screening evaluation is not limited to a compound (drug), but may be a stimulus such as light.

[0161] Furthermore, the objects to be aspirated in step S207 in FIG. 14 are not limited to specific (minor) cells or tissues, and major cells (cells in the first state) may also be aspirated and analyzed as a positive control.

[0162] <Modification> A modified example of the embodiment will be described below. In the following modified example, an example of performing a combined analysis of morphological (image) information and genetic information will be described. Fig. 17 is a flowchart of the process in the modified example according to the present embodiment. Note that the following process is performed, for example, in the molecular analysis process in step S208 in Fig. 14.

[0163] (Step S401) The image analysis unit 33 performs image analysis on an image of a sample.

[0164] (Step S402) The aspirated cell selection unit 23 selects a first cell (a cell in a first state, a cell of major proportions) based on the image analysis result. Then, the imaging and aspirating device 3 aspirates the first cell in response to an aspirating instruction from the control device 2.

[0165] (Step S403) The aspirated cell selection unit 23 selects a second cell (a cell in a second state, a cell of minor proportion) based on the image analysis result. Then, the photographing and aspirating device 3 aspirates the second cell in response to an aspirating instruction from the control device 2.

[0166] (Step S404) Analysis device 4 performs genetic analysis on each of the first cell and the second cell.

[0167] (Step S405) The estimation unit 26 compares the results of the gene analysis.

[0168] (Step S406) The estimation unit 26 causes the display unit 22 to display the analysis result.

[0169] <Third embodiment> In the above embodiment, an example of making an estimation based on the information stored in DB5 has been described, but the present invention is not limited to this. In addition to making an estimation based on the information stored in DB5, the drug discovery screening system 1 may also perform processing using the following information.

[0170] [Example of the configuration of drug discovery screening system 1] Fig. 1 is a block diagram showing an example of the configuration of a drug discovery screening system 1 according to this embodiment. As shown in Fig. 1, the drug discovery screening system 1 includes a control device 2, an imaging and aspirating device 3 (imaging section, aspirating section), an analysis device 4-1, an analysis device 4-2, ..., and a DB 5. In the following description, when one of the analysis devices 4-1, 4-2, ... is not specified, it will be referred to as an analysis device 4. Note that the drug discovery screening system 1 includes at least one analysis device 4.

[0171] The control device 2 includes an operation unit 21, a display unit 22, an aspirated cell selection unit 23 (discrimination unit), a DB creation unit 24, a feature extraction unit 25, an estimation unit 26, and a control unit 27. The imaging and suction device 3 includes a control unit 31 , an imaging and suction unit 32 , and an image analysis unit 33 . The control device 2 and the imaging and suction device 3 are connected to each other via a wired or wireless line. The control device 2 and the analysis device 4 are connected to each other via a wired or wireless line.

[0172] In this embodiment, in addition to the database of the first embodiment, DB5 stores, for each cell or cell type, characteristics of images of cells or tissues, such as shape, size, the color of the cell when stained with a dye and the effect of a drug is apparent, and the color of the cell when stained with a dye and the effect of a drug is not apparent.

[0173] [Drug discovery screening process] Next, an example of a drug discovery screening process procedure will be described with reference to FIG. 18 and FIG. 19. FIG. 18 and FIG. 19 are flow charts of the drug discovery screening process according to this embodiment. During screening, the operator places an aspirating tip 324 on the tip rack 325 according to the purpose of aspirating. For example, when aspirating a cellular component, a nanospray tip is placed, and when aspirating a single cell, a normal aspirating tip is placed. When the size of the cell is unknown, aspirating tips 324 of a plurality of sizes may be placed on the tip rack 325 in advance. Then, based on the image processing result, the imaging and aspirating device 3 may select an aspirating tip 324 according to the control of the control device 2.

[0174] (Step S501) An operator prepares a cell sample (e.g., cancer cells). Next, the operator prepares a specimen by adding a candidate compound to the prepared cell sample. Next, the operator places the specimen in a cell culture well plate 5. Note that the operator may perform, for example, fluorescent staining as necessary. Next, the operator sets the cell culture well plate 5 on the XY stage 3213 of the imaging and suction unit 32. The control unit 27 detects that the cell culture well plate 5 has been set on the XY stage 3213. Note that the control unit 27 may detect this based on the result of the operator operating the operation unit 21 of the control device 2, may detect this based on an image captured by the imaging unit 3211, or may detect this based on a sensor provided in the imaging and suction unit 32.

[0175] (Step S502) The photographing and aspirating unit 32 photographs the entire sample in response to a photographing instruction from the control device 2. Then, the image analysis unit 33 analyzes the shape and the like of the photographed image by image processing. Then, the image analysis unit 33 outputs the image processing result to the control device 2. Then, the aspirated cell selection unit 23 performs morphological evaluation based on the image analysis result output by the image analysis unit 33, with reference to the information stored in the DB5.

[0176] (Step S503) The aspirated cell selection unit 23 performs a drug efficacy judgment based on the result of the morphological evaluation. If the drug efficacy judgment results in an effective drug (Step S503; Effective), the aspirated cell selection unit 23 proceeds to processing of Step S505. If the drug efficacy judgment results in an ineffective drug (Step S503; Ineffective), the aspirated cell selection unit 23 proceeds to processing of Step S504.

[0177] (Step S504) The control unit 27 causes information indicating that the compound determined to be problematic is to be excluded to be displayed on the display unit 22. Subsequently, the control unit 27 returns the process to step S501.

[0178] (Step S505) The aspirated cell selection unit 23 refers to the information stored in the DB5 based on the image processing result for the image of the entire sample, and determines whether the sample contains cells or tissues in which the drug effect is being exerted, or whether the sample contains cells or tissues in which the drug effect is not being exerted. If the aspirated cell selection unit 23 subsequently determines that all cells have the same morphology, it proceeds to the process of step S512 (FIG. 19). If the aspirated cell selection unit 23 determines that the sample contains cells or tissues in which the drug effect is not being exerted, that is, if it determines that some cells have different morphologies, it proceeds to the process of step S506.

[0179] (Step S506) The imaging and suction unit 32, in response to an imaging instruction from the control device 2, captures an image of the specific area.

[0180] (Step S507) The image analysis unit 33 performs image processing on the captured image and outputs the image analysis result to the control device 2.

[0181] (Step S508) The aspirated cell selection unit 23 determines the cells or tissues to be aspirated based on the image processing result and the information stored in the DB 5. Next, the control unit 27 generates an aspirating instruction based on the cells or tissues to be aspirated determined by the aspirated cell selection unit 23, and outputs the generated aspirating instruction to the imaging and aspirating device 3.

[0182] (Step S509) In response to a suction instruction from the control device 2, the imaging and suction unit 32 suctions the desired cell or tissue.

[0183] (Step S510) Analysis device 4 performs analysis (for example, genetic analysis) on the sucked cells or tissue. Analysis device 4 outputs the analysis results to control device 2.

[0184] (Step S511) The estimation unit 26 refers to the analysis results output by the analysis device 4 and the information stored in the DB 5 to determine whether the kinetics and toxicity of the added compound can be improved by structural modification. If the estimation unit 26 determines that the kinetics and toxicity can be improved by structural modification (Step S511; improvement possible), it proceeds to processing of step S512 (FIG. 19). If the estimation unit 26 determines that the kinetics and toxicity cannot be improved by structural modification (Step S511; improvement not possible), it proceeds to processing of step S504.

[0185] (Step S512) The operator performs structural modification on the compound used in step S501. Then, the operator adds the structurally modified compound to the cell sample prepared in step S501. Next, the operator puts the sample into the cell culture well plate 5. The operator performs, for example, fluorescent staining as necessary. Next, the operator removes the cell culture well plate 5 used in steps S501 to S511 from the XY stage 3213 of the imaging and suction device 3. Next, the operator sets the cell culture well plate 5 on which the specimen of the cell sample to which the structurally modified compound has been added is placed, on the XY stage 3213 of the imaging and suction device 3. The imaging and suction device 3 detects that the cell culture well plate 5 has been set on the XY stage 3213 of the imaging and suction device 3.

[0186] (Step S513) The analysis device 4 performs, for example, genetic analysis on the cells contained in the sample to check the behavior. During the behavior check, the control device 2 controls the imaging and suction device 3 to suction cells or tissues from the sample.

[0187] (Step S514) The estimation unit 26 determines whether or not there is a problem with the movement, based on the result of the movement confirmation performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with the movement (Step S514; No problem), the estimation unit 26 proceeds to the process of Step S515. If the estimation unit 26 determines that there is a problem with the movement (Step S515; Problem), the estimation unit 26 proceeds to the process of Step S504 (FIG. 18).

[0188] (Step S515) The analysis device 4 evaluates the physical properties of the added compound.

[0189] (Step S516) The estimation unit 26 determines whether or not there is a problem with the physical properties based on the result of the physical property evaluation performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with the physical properties (Step S516; No problem), the estimation unit 26 proceeds to processing of Step S517. If the estimation unit 26 determines that there is a problem with the physical properties (Step S516; Problem), the estimation unit 26 proceeds to processing of Step S504 (FIG. 18).

[0190] (Step S517) The analysis device 4 performs toxicity evaluation.

[0191] (Step S518) The estimation unit 26 determines whether or not there is a problem with toxicity based on the result of the physical property determination performed by the analysis device 4. If the estimation unit 26 determines that there is no problem with toxicity (Step S518; No problem), the estimation unit 26 proceeds to processing of Step S519. If the estimation unit 26 determines that there is a problem with toxicity (Step S216; Problem), the estimation unit 26 proceeds to processing of Step S504 (FIG. 18).

[0192] (Step S519) The control unit 17 displays information indicating that there were no problems in the screening process on the display unit 22. In response to this, clinical trials are conducted on humans using the drug (compound). After the process, the drug discovery screening process is terminated.

[0193] [First Example] In this embodiment, an example of using morphological information (cell cycle) and genetic information (comprehensive analysis) will be described. In this embodiment, as a specific example, a case of using a drug that stops the cell cycle of cancer cells and suppresses abnormal proliferation will be described.

[0194] First, the sample is stained with a fluorescent dye to confirm the cell cycle, and then the aspirated cell selection unit 23 judges whether the cell is in the G1 cycle or a cell in a phase other than G1 based on the fluorescence information. Next, the aspirated cell selection unit 23 controls so as to aspirate one cell in the G1 phase (cell in the first state) as a control sample. The imaging and aspirating device 3 aspirates the cell in the G1 phase from the specific region. In addition, the aspirated cell selection unit 23 controls so as to aspirate one cell other than the G1 phase (cell in the second state) as a target sample. The analysis device 4 simultaneously extracts DNA and RNA from the aspirated cell and quantifies the amount of each gene. Furthermore, the analysis device 4 confirms differences in gene expression and DNA sequences between the control sample and the target sample. This makes it possible to estimate the reason why a drug effect was not obtained in some cells, and to confirm differences in response to a drug due to differences in the cell cycle.

[0195] When preparing cell samples, the efficiency of testing can be improved by seeding multiple types of cells (cells with different resources, etc.) in the same well. With conventional screening methods, seeding multiple cells in the same well makes it difficult to separate the cell types, so it was necessary to test each cell type in a separate well. In contrast, in this embodiment, it is possible to isolate a single cell and also to confirm the origin of the cell by analyzing the DNA of the cell, making it possible to analyze a mixed sample.

[0196] For example, when screening for drugs to treat lung cancer, the drug is added to lung cancer cells and tested. In this case, only one type of cell is seeded in one well, meaning that only samples with limited conditions such as country A, age B, medical history C, and medication history D, either male or female, can be tested in one well. When screening hundreds of thousands of compounds, it is not efficient to evaluate the efficacy of several hundred types of cells. However, if the evaluation is performed using biased samples, efficacy or toxicity may be overlooked. In contrast, according to the present embodiment, efficacy evaluation of multiple samples on a minimum scale can be realized.

[0197] [Second Example] In the second embodiment, an example of using morphological information (cell position information) and genetic information (comprehensive analysis) will be described. In this embodiment, as a specific example, a case of confirming the elimination mechanism of normal cells that eliminates cancer cells will be described.

[0198] First, the aspirated cell selection unit 23 acquires position information of each cell based on the image processing result, and determines whether or not the cell is in contact with a cancer cell. Next, the aspirated cell selection unit 23 outputs an aspirating instruction to the imaging and aspirating device 3 to aspirate one cell that is not in contact with the cancer cells as a control sample.

[0199] The imaging and suction device 3 aspirates one cell that is in contact with the cancer cell as a target sample. The analysis device 4 performs RNA-seq on the sucked cells to quantify the gene amount. The analysis device 4 identifies differences in gene expression between the control sample and the target sample.

[0200] As a result, this embodiment makes it possible to confirm genes that are specifically increased or decreased in normal cells in contact with cancer cells, and to infer the mechanism by which normal cells recognize and eliminate cancer cells. Furthermore, this embodiment makes it possible to confirm changes in gene expression that occur upon contact with a specific cell type.

[0201] The reason for collecting cells in contact with cancer cells in this way is that it is believed that the progression of cancer is influenced not only by the cancer cells themselves, but also by the environment (microenvironment) created by the normal cells around the cancer cells.

[0202] When preparing cell samples, seeding multiple types of cells (e.g. epithelial cells and mesenchymal cells) in the same well allows tests to be performed in an environment closer to that of the living body. In conventional screening methods, seeding multiple cells in the same well makes it difficult to separate the cell types, so tests have generally been performed using a single cell type. In contrast, in this embodiment, it is possible to separate a single cell, and by identifying the cell based on its morphology and analyzing its DNA, it is possible to confirm its origin, making it possible to analyze a mixed sample.

[0203] [Third Example] In this example, an example of using morphological information (cell migration distance) and genetic information (comprehensive analysis) will be described. In this example, as a specific example, a case of confirming expressed genes of cancer cells migrating in a collagen gel will be described.

[0204] The control unit 27 outputs an image capturing instruction to the image capturing and aspirating device 3 so as to perform time lapse image capturing and record the movement distance of each cell. The aspirated cell selection unit 23 selects cells whose movement distance is equal to or less than a first threshold value and cells whose movement distance is equal to or more than a second threshold value, based on the image processing result. Note that the second threshold value is greater than the first threshold value. The aspirated cell selection unit 23 outputs an aspirating instruction to the imaging and aspirating device 3 to aspirate one cell whose movement distance is equal to or less than the first threshold value as a control sample.

[0205] Moreover, the imaging and aspirating device 3 aspirates one cell whose movement distance is equal to or greater than the second threshold value as a target sample. The analysis device 4 performs RNA-seq on the aspirated cells to quantify the amount of genes.

[0206] As a result, according to this embodiment, it is possible to confirm genes that are specifically increased or decreased in highly mobile cancer cells (highly malignant cells), and to estimate drugs that are effective against more malignant cells. Furthermore, according to this embodiment, it is possible to confirm the relationship between cell migration and gene expression. The reason why cells that have migrated a long distance are aspirated is because, in the field of cancer, cells with a high degree of mobility are considered to be highly malignant cells that are prone to infiltration and metastasis.

[0207] [Fourth Example] In Example 4, an example of using morphological information (morphology of a cell population) and genetic information (comprehensive analysis) will be described. In this Example, as a specific example, a case of confirming undifferentiated state during culture of undifferentiated cells will be described.

[0208] First, the image analysis unit 33 converts the cell density and the smoothness of the contour shape of a colony formed by undifferentiated cells into numerical values ​​by image analysis, and stores the numerical values ​​in the DB 5 as morphological information. Based on the image analysis results, the aspirated cell selection unit 23 selects cells located in the center of a colony with a high cell density and a smooth outline. The aspirated cell selection unit 23 also selects cells located in the outline of a colony with a low cell density and an uneven outline. Furthermore, the aspirated cell selection unit 23 selects cells that have fallen out of the colony and are surviving alone.

[0209] The aspirated cell selection unit 23 outputs an aspiration instruction to the photographing and aspirating device 3 to aspirate one cell located at the center of a colony with a high cell density and a smooth outline as the control sample C. The aspirated cell selection unit 23 also outputs an aspiration instruction to the photographing and aspirating device 3 to aspirate one cell located at the outline of a colony with a low cell density and an uneven outline as the target sample A. The aspirated cell selection unit 23 outputs an aspiration instruction to the photographing and aspirating device 3 to aspirate one cell that has fallen out of the colony and is living alone as the target sample B.

[0210] The analysis device 4 performs RT-qPCR (real-time qPCR) on the aspirated cells to quantify the amount of undifferentiation marker genes. RNA-seq (sequencing) may also be used. The analysis device 4 confirms the differences in gene expression between samples A, B, and C.

[0211] This makes it possible to confirm whether the entire well, including A, B, and C, maintains an undifferentiated state. Furthermore, this embodiment makes it possible to confirm changes in the morphology of cell populations due to differences in gene expression.

[0212] The undifferentiated state can be roughly estimated from image information. For accurate evaluation, genetic analysis is required. For this reason, in this embodiment, cells are classified by arbitrary parameters based on the image analysis results, and one cell from each of the different classifications is aspirated and subjected to comprehensive genetic analysis.

[0213] In this embodiment, if a correlation between morphological information and genetic information is confirmed, it will be possible to confirm undifferentiated state based on morphological information alone.

[0214] Although an example of performing gene analysis in the molecular analysis in step S208 of Fig. 14 has been described, multivariate analysis may be performed on the gene analysis results and morphological information. As a result, according to this embodiment, it may be possible to discover a new correlation between morphology and gene expression.

[0215] <Additional Notes> (1) an imaging unit performs imaging of a specimen in which a candidate drug is added to a cell sample, the imaging unit imaging a plurality of the cell samples; a discrimination unit performs image processing on the captured image, and discriminates whether or not a first state cell is present in the plurality of cell samples and whether or not a second state cell is present in the plurality of cell samples based on a result of the image processing; the imaging unit images an area in which the cells in the second state are present when the cells in the second state are present; an aspirator aspirating the cells in the second state; An analysis unit analyzes components of the aspirated cells in the second state; The control unit determines whether or not to proceed with the drug discovery screening process based on the analyzed results. Drug discovery screening methods. (2) the cell in the first state is a cell or tissue in the sample in which the effect of the candidate drug is manifested; The drug discovery screening method according to (1), wherein the cells in the second state are cells or tissues in which the effect of the candidate drug is not observed in the sample. (3) The drug discovery screening method described in (1) or (2), wherein the discrimination unit analyzes the morphology of the multiple cells based on the captured image, determines whether or not the effect of the added candidate drug is being seen based on the results of the morphological analysis, and, if the effect of the added candidate drug is being seen, determines whether or not a first state cell or a second state cell is present among the multiple cells. (4) The drug discovery screening method according to any one of (1) to (3), wherein the components analyzed by the analysis unit are at least one of a compound possessed by the aspirated cell, a compound produced by the aspirated cell, a compound produced by the aspirated surrounding cells, a compound added to a culture supernatant of the aspirated cell, a compound administered to an individual of the aspirated cell, and a compound ingested by the aspirated cell. (5) The drug discovery screening method according to any one of (1) to (4), wherein the imaging unit images the stained specimen so as to include a plurality of the cell samples. (6) The drug discovery screening method described in (3), wherein the discrimination unit analyzes at least one of the following morphology: area of ​​the cytoplasm of the cell, area of ​​the nucleus of the cell, circularity of the cytoplasm of the cell, and kurtosis of the cytoplasm of the cell. (7) A drug discovery screening method described in any one of (1) to (6), wherein the suction unit also suctions cells in the first state, and the analysis unit analyzes components of the suctioned cells in the second state, and compares the analysis results for the cells in the first state with the analysis results for the cells in the second state. (8) A drug discovery screening system including an imaging unit, an aspirator, an image processing device, a control device, and an analyzer, The control device controls the imaging of the imaging unit, controls the suction operation of the suction device based on the result of image processing by the image processing device, and determines whether or not to proceed with the drug discovery screening process based on the result of analysis by the analysis device; The imaging unit, in response to control by the control device, images a specimen in which a candidate drug has been added to a cell sample, so as to include a plurality of the cell samples, and, when cells in a second state different from the cells in the first state are present, images an area in which the cells in the second state are present; the image processing device performs image processing on the captured image, and determines whether or not the first state cells and the second state cells are present in the plurality of cell samples based on a result of the image processing; the suction device, when a cell in a second state is present, aspirates the cell in the second state in response to control by the control device; The analysis device analyzes components of the aspirated cells in the second state. Drug discovery screening system.

[0216] In addition, a program for realizing all or part of the functions of the control device 2 or the photographing and suction device 3 in the present invention may be recorded in a computer-readable recording medium, and the program recorded in the recording medium may be read into a computer system and executed to perform all or part of the processing performed by the control device 2 or the photographing and suction device 3. In addition, the term "computer system" as used herein includes hardware such as an OS and peripheral devices. In addition, the term "computer system" also includes a WWW system equipped with a homepage providing environment (or display environment). In addition, the term "computer-readable recording medium" refers to portable media such as flexible disks, optical magnetic disks, ROMs, and CD-ROMs, and storage devices such as hard disks built into a computer system. In addition, the term "computer-readable recording medium" also refers to a storage device that holds a program for a certain period of time, such as a volatile memory (RAM) inside a computer system that becomes a server or a client when a program is transmitted via a network such as the Internet or a communication line such as a telephone line.

[0217] The above program may also be transmitted from a computer system in which the program is stored in a storage device or the like to another computer system via a transmission medium, or by transmission waves in the transmission medium. Here, the "transmission medium" that transmits the program refers to a medium that has the function of transmitting information, such as a network (communication network) such as the Internet or a communication line (communication line) such as a telephone line. The above program may also be for realizing part of the above-mentioned functions. Furthermore, it may be a so-called difference file (difference program) that can realize the above-mentioned functions in combination with a program already recorded in the computer system.

[0218] The above describes the form for carrying out the present invention using an embodiment, but the present invention is not limited to such an embodiment, and various modifications and substitutions can be made within the scope that does not deviate from the gist of the present invention. [Explanation of symbols]

[0219] 1. Drug discovery screening system, 2...Control device, 3...Photographic suction device, 4-1,4-2,4…Analysis device, 5…cell culture well plate, 21...Operation unit, 22...display section, 23...Aspiration cell selection unit, 24...DB creation department, 25...Feature extraction unit, 26...Estimation section, 27...Control unit, 31...Control unit, 32...photography suction unit, 33...Image analysis unit, 321...image cell acquisition unit, 322...Suction part, 323…XYZ Stage, 324...suction tip, 325…Tip rack, 326... Sample rack, 3211…Camera Department, 3212…Bright field illumination, 3213…XY stage

Claims

1. A sample containing a candidate drug was then photographed. The captured image is processed, acquiring morphological information on the shape of cells contained in the cell sample based on the result of the image processing, selecting one cell to be aspirated based on the morphological information, and aspirating the selected one cell or a cellular component of the selected one cell; Analyzing the aspirated single cell; storing the morphological information and molecular information obtained based on the analysis results in a database for each of the analyzed cells, extracting features indicating a relationship between the molecular information and the morphological information stored in the database, storing the extracted features in the database in association with the molecular information and the morphological information stored in the database, and creating a database related to the shapes of the cells; A screening sample is a sample in which a candidate drug to be screened is added to a cell sample, and the cell sample is photographed so as to include a plurality of the cell samples; using the morphological information acquired based on the result of image processing of the captured image, and referring to the database, estimating the state of the cells contained in the sample; A novel drug discovery screening method.

2. The method for screening novel drugs according to claim 1 , wherein the morphological information includes information indicating a position of a cell or a position of a nucleus.

3. The method for screening novel drugs according to claim 1 or claim 2, wherein the morphological information includes at least one of a cell area, a nuclear area, a cell perimeter, a nuclear perimeter, a cell major axis, a nuclear major axis, a cell minor axis, a nuclear minor axis, a cell apex ratio, and a nuclear apex ratio.

4. The molecular information is at least one of gene information, protein information, peptide information, amino acid information, lipid information, carbohydrate information, and mass information. The method for screening novel drugs according to any one of claims 1 to 3.

5. the molecular information is genetic information, The feature amount is a correlation coefficient between the morphological information and the genetic information. The method for screening novel drugs according to any one of claims 1 to 3.

6. an imaging and aspirating device that images a sample in which a candidate drug is added to a cell sample and aspirates cells contained in the cell sample; an analysis device that analyzes the cells aspirated by the imaging and aspirating device; A control device that controls the imaging and suction device and the analysis device; Equipped with the control device acquires morphological information on the shape of cells contained in the cell sample based on a result of image processing of an image obtained by the photographing and aspirating device photographing the sample, selects one cell to be aspirated based on the morphological information, and causes the photographing and aspirating device to aspirate the selected one cell or a cellular component of the selected one cell; and a feature extraction unit that stores the morphological information and molecular information obtained by the analysis device analyzing the aspirated single cell in a database for each analyzed single cell, extracts features that indicate a relationship between the molecular information and the morphological information stored in the database, associates the extracted features with the molecular information and the morphological information stored in the database, and stores the extracted features in the database to create a database related to the shapes of the cells; an estimation unit that estimates the state of the cells contained in a screening sample, which is a sample in which a candidate drug to be screened is added to a cell sample, by referring to the database using the morphological information acquired based on the result of image processing of an image obtained by photographing and aspirating the cell sample so as to include a plurality of the cell samples; Equipped with New drug discovery screening system.

7. a cell-aspirating selection unit which acquires morphological information on the shape of cells contained in the cell sample based on the result of image processing of an image obtained by photographing a specimen in which a candidate drug has been added to the cell sample, selects one cell to be aspirated based on the morphological information, and aspirates the selected one cell or a cellular component of the selected one cell; a feature extraction unit that stores the morphological information and molecular information obtained by analyzing the aspirated single cell in a database for each analyzed single cell, extracts features indicating a relationship between the molecular information and the morphological information stored in the database, associates the extracted features with the molecular information and the morphological information stored in the database, and stores the extracted features in the database to create a database related to the shape of the cell; an estimation unit that estimates the state of the cells contained in a screening sample, which is a cell sample to which a candidate drug to be screened has been added, by referring to the database and using the morphological information acquired based on the result of image processing of an image obtained by photographing a plurality of the cell samples; A novel drug discovery screening control device comprising:

Citation Information

Patent Citations

  • Use of novel disintegrin metalloproteases, mutants, fragments, etc.

    JP2001514494A

  • Screening method and screening apparatus

    JP2007020449A

  • Drug-screening system

    JP2008136464A

  • Drug discovery screening apparatus

    JP2010210237A

  • Method for evaluating physiological state of yeast by using cell form quantification value

    JP2011030494A